Log In
BCIQ
Print this Print this
 

tesevatinib (XL647) (formerly KD019)

  Manage Alerts
Collapse Summary General Information
Company Symphony Evolution Inc.
DescriptionTyrosine kinase inhibitor (TKI) that targets EGFR, VEGF receptor 2 (VEGFR-2; KDR/Flk-1), HER2 and Src
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionKinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today